Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency
Authors:
- 8 March 1996
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 36 (3) , 206-215
Abstract
Ondansetron is primarily eliminated via hepatic metabolism; thus, liver disease may affect its clearance. The pharmacokinetics of ondansetron in patients with different degrees of hepatic insufficiency (N = 12 with hepatic impairment, as categorized by Pugh's classification method) were assessed and the results compared with results for age‐ and gender‐matched control subjects with normal liver function (n = 12). A secondary objective was to correlate the Pugh method of assessing hepatic impairment and quantitative metabolic markers used to assess hepatic function (antipyrine clearance and indocyanine green clearance) with changes in the pharmacokinetics of ondansetron. This was an open‐label study in which 8 mg ondansetron was given orally and intravenously, following a randomized crossover design. Clearance of ondansetron was lower among patients with hepatic impairment than control subjects. After a single, oral dose of ondansetron, mean absolute bioavailability increased markedly with increased hepatic insufficiency (approaching 100% in the group with severe hepatic impairment versus 66% for control subjects). These data suggest that there is a reduced first‐pass effect in patients with liver disease resulting in a higher AUC0‐∞. A correlation existed between clearance of ondansetron and decreased antipyrine clearance; a smaller correlation existed between ondansetron clearance and indocyanine green clearance. Mean percent of ondansetron bound to plasma proteins was significantly lower in patients with liver disease than in control subjects. None of the patients experienced any severe adverse reactions attributed to ondansetron. A reduction in the clearance of ondansetron is associated with increasing degrees of hepatic insufficiency; therefore, patients with severe hepatic impairment (Pugh score of>9) should have their daily dose of ondansetron limited to 8 mg (or 0.15 mg/kg).Keywords
This publication has 15 references indexed in Scilit:
- OndansetronSouthern Medical Journal, 1993
- Prevention of Postoperative Nausea and Vomiting Using Ondansetron, a New, Selective, 5-HT3 Receptor AntagonistAnesthesia & Analgesia, 1991
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONISTThe Lancet, 1987
- Lack of Effect of Histamine H2‐Receptor Antagonists on Indocyanine Green Disposition Measured by Two MethodsThe Journal of Clinical Pharmacology, 1984
- Assay of Antipyrine and Its Primary Metabolites in Plasma, Saliva and Urine by High-Performance Liquid Chromatography and Some Preliminary Results in ManPharmacology, 1979
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Clearance of Antipyrine‐Dependence of Quantitative Liver FunctionEuropean Journal of Clinical Investigation, 1974
- Clearance of Antipyrine‐Dependence of Quantitative Liver FunctionEuropean Journal of Clinical Investigation, 1974
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973